NMTC vs PATH · rev $3.5M vs P/E 19, rev $1.61B
Neuroone Medical Technologies Corp (NMTC) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Neuroone Medical Technologies Corp (NMTC) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported NMTC revenue for 2024-09-30 was $3.5M. Net income was -$12.3M. Revenue was up 76.9% from 2023-09-30 to 2024-09-30. NMTC currently screens at market cap $35.5M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
NMTC currently screens at market cap $35.5M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the NMTC and PATH stock pages for the full models.
Not investment advice.